Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Wijngaart, Hanneke, Beekhof, Robin, Knol, Jaco C., Henneman, Alex A., de Goeij-de Haas, Richard, Piersma, Sander R., Pham, Thang V., Jimenez, Connie R., Verheul, Henk M. W., Labots, Mariette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631096/
https://www.ncbi.nlm.nih.gov/pubmed/37940875
http://dx.doi.org/10.1186/s12014-023-09437-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631096/
https://www.ncbi.nlm.nih.gov/pubmed/37940875
http://dx.doi.org/10.1186/s12014-023-09437-6

Ejemplares similares